Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares are trading lower on Friday as the company faces challenges following a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding its Marketing Authorization Application for arimoclomol for Niemann-Pick disease type C (NPC).
NPC is a rare, progressive genetic disorder that impairs the body’s ability to transport cholesterol and other lipids within cells. It causes these fats to accumulate in the organs.
• Zevra Therapeutics shares are retreating from recent levels. Why is ZVRA stock falling?
Zevra Plans CHMP Re-Examination for Arimoclomol
The rare disease company plans to request a re-examination of the CHMP’s negative opinion and will provide a detailed explanation to support its case.
The company continues to advocate for patient access to arimoclomol through its global Expanded Access Program, emphasizing its commitment to the Niemann-Pick disease community.
ZVRA Technical Outlook: Oversold Signal and Key Levels
The stock’s current price of $9.74 places it significantly below its moving averages, with the 20-day simple moving average (SMA) at $13.20, indicating a 24.3% decline from this level.
The Relative Strength Index (RSI) is currently at 28.91, suggesting that the stock is in oversold territory, which may indicate potential for a rebound if buying interest returns.
- Key Resistance: $11.50 — Nearby level where rebounds can stall.
- Key Support: $9.50 — Nearby level where buyers previously stepped in.
ZVRA Earnings Preview and Analyst Price Targets
The countdown is on: Zevra Therapeutics is set to report earnings on Aug. 5 (confirmed).
- EPS Estimate: 14 cents (Down from $1.24)
- Revenue Estimate: $33.57 million (Up from $25.90 million)
- Valuation: P/E of 6.2x (Indicates value opportunity)
Analyst Consensus & Recent Actions: The stock carries a Buy rating with a consensus price forecast of $24.54. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Maintains target to $26 on June 23)
- Canaccord Genuity: Buy (Maintains target to $29 on June 11)
- Maxim Group: Buy (Raises target to $35 on June 10)
How ZVRA Ranks On Value and Momentum
Below is the Benzinga Edge scorecard for Zevra Therapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Value: 54.2 — The stock is trading at a moderate valuation relative to its peers.
- Momentum: 84.16 — Stock is outperforming the broader market.
Stock Slides After CHMP Opinion
ZVRA Stock Price Activity: Zevra Therapeutics shares were down 24.40% at $9.47 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment